Lyra Therapeutics Posts 85% Q2 Loss Drop

Lyra Therapeutics (NASDAQ:LYRA), a clinical-stage biotechnology company focused on chronic rhinosinusitis (CRS) treatments, reported its second quarter 2025 results on August 12, 2025. The most noteworthy item was the recent pivotal ENLIGHTEN 2 clinical trial win for its primary product candidate, paired with significant cost reductions and new financing. The GAAP EPS loss of $5.51 was less negative than analyst expectations, but GAAP revenue was $0.18 million, which was below the GAAP estimate of $0.29 million. Cost controls led to a much lower GAAP net loss compared to Q2 2024. Overall, the period was highlighted by clinical progress, disciplined spending, and while the company remains reliant on future regulatory milestones. Source: Analyst estimates for the quarter provided by FactSet. Lyra Therapeutics develops bioabsorbable implant devices designed to treat chronic rhinosinusitis, an inflammatory nasal condition affecting millions of people. Its lead product candidate, LYR-210, is a long-acting implant intended to deliver steroid therapy directly to the nasal lining over six months. The company is targeting patients who have not responded to standard medical management and may otherwise require surgery.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool